Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
RAVICHANDRAN ASHWIN claimed six wickets after a first-innings century with the bat to inspire India to a 280-run thrashing of Bangladesh in the first Test on Sunday (22).
The visitors arrived in Chennai in confident mood following a historic victory in Pakistan but they were no match for an Indian team for whom Rishabh Pant celebrated a triumphant return from a serious car crash.
Bangladesh have still never beaten India in Tests in 14 attempts, losing 12 and drawing two.
Bangladesh were bowled out for 234 in the first session of an overcast day four while chasing a victory target of 515.
Skipper Najmul Hossain Shanto top-scored with 82 after he and overnight partner Shakib Al Hasan resisted in a 48-run partnership, Bangladesh having resumed the day on 158-4.
The hosts took an emphatic 1-0 lead in the two-match series as they look to extend their advantage at the top of the World Test Championship rankings.
"It was a great result looking at what lies ahead," skipper Rohit Sharma said after India made an ominous start to a fresh Test season of 10 matches.
Hometown hero Ashwin struck first to end a stubborn overnight stand by getting Shakib caught at short-leg for 25.
The spinner, who took three wickets on day three, then dismissed Mehidy Hasan Miraz for eight to bag his 37th five-wicket haul, equalling the late Shane Warne.
Muttiah Muralitharan remains well out in front with 67.
The feat added to Ashwin's heroics after his 113 guided the hosts to 376 in the first innings.
"He's always there for us over the years," Rohit said of the 38-year-old warhorse, who was named man of the match.
"I don't know if I speak here (that) it'll be enough to cover what he does for the team. He looks like he's never out of the game."
Left-arm spinner Ravindra Jadeja removed Litton Das for one after the wicketkeeper-batsman edged the ball to Rohit at first slip.
Jadeja also ended Najmul's valiant stand and took three wickets for the innings.
Spin twins Ashwin and Jadeja had played a key batting role in the first innings when their 199-run seventh-wicket stand lifted India from a precarious 144-6 to a challenging total on the first day.
India declared their second innings at 287-4 on day three after centuries from Shubman Gill, who hit an unbeaten 119, and the returning Pant, who made 109, flattened the opposition.
Gill and the left-handed Pant, who was playing his first Test since a serious car crash in December 2022, put on 167 runs for the fourth wicket.
"I just enjoyed batting and got a little bit emotional," Pant said of his celebration after his sixth Test ton.
"But at the end of the day, being in the field gives me more pleasure than anything else."
The Test was Virat Kohli's first since the birth of his second child made him miss India's 4-1 victory over England at home this year. Kohli scored just six and 17.
The home bowlers led by Jasprit Bumrah handed India an early advantage after they bundled out Bangladesh for 149 in their first innings.
Bangladesh have to work on their first innings batting ahead of the second Test, said skipper Najmul.
"Top of the order we have to be careful and put some runs, that is one learning from this match. Going forward all the batters think that they can come back."
Bangladesh pace bowler Hasan Mahmud claimed five wickets in the first innings and reduced India to 34-3 in the first hour of play.
The two teams now head to the northern city of Kanpur for the second Test starting on Friday (27).
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.